This review outlines chemical strategies to alter amyloid aggregation in neurodegenerative diseases, indicating new therapeutic insights.
Amyloidogenic peptides and proteins, including amyloid-β, tau, and α-synuclein, are key pathological factors in neurodegenerative diseases. Their misfolding and self-assembly into toxic oligomers and fibrils disrupt cellular homeostasis and lead to neuronal dysfunction. To address these pathogenic processes, diverse chemical strategies have been developed employing nanomaterials, small organic molecules, and metal complexes. These reagents chemically modify amyloidogenic peptides and proteins, thereby altering their aggregation pathways, attenuating associated toxicity, and demonstrating in vivo efficacy. In this review, we outline and discuss the design principles and mechanistic bases of these chemical interventions, with some examples that demonstrate anti-amyloidogenic effects. Collectively, these advances underscore the power of chemistry to modulate amyloid aggregation and provide mechanistic insights that can guide the development of innovative therapeutic strategies for amyloid-driven neurodegeneration.
No takes yet. Share an insight, caveat, or question.
Na et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: